Factor Xa Inhibitors
- Name
- Factor Xa Inhibitors
- Accession Number
- DBCAT001775
- Description
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
- ATC Classification
- Drugs
Drug Drug Description Rivaroxaban A factor Xa inhibitor used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). May also be used as thrombosis prophylaxis in specific situations. Apixaban An anticoagulant used for the prophylaxis of stroke and systemic embolism in nonvalvular atrial fibrillation, and deep vein thrombosis(DVT) leading to pulmonary embolism(PE), including in patients after a hip or knee replacement surgery. Edoxaban A novel oral anticoagulant used for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Fondaparinux An anticoagulant used to prevent venous thromboembolism, to treat deep vein thrombosis, and to improve survival following myocardial infarction. Idraparinux Investigated for use/treatment in thrombosis, venous thromboembolism, strokes, heart disease, and atrial fibrillation. Otamixaban Investigated for use/treatment in thrombosis. Letaxaban Letaxaban has been used in trials studying the treatment and prevention of Venous Thromboembolism and Acute Coronary Syndrome. Darexaban Darexaban has been used in trials studying the prevention and basic science of Japanese, Caucasian, Thromboembolism, Pharmacodynamics, and Pharmacokinetics, among others. Betrixaban A Factor Xa inhibitor used for prophylaxis of venous thromboembolism in hospitalized patients. Antithrombin Alfa A recombinant antithrombin used to treat peri-operative and peripartum thromboembolic events in hereditary antithrombin deficiency. GW-813893 Not Available Dabigatran Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate. - Drugs & Drug Targets